NAKO Gesundheitsstudie
NAKO Gesundheitsstudie is a German non-profit research association operating the country's largest population-based longitudinal health cohort study, following 200,000+ participants across 18 study centers and serving academic researchers with access to multi-omics, imaging, and survey data.
- Company typePrivate
- Founded2014
- Headquarters—
- Headcount11–50
- GTM typeB2B
- OfferingServices
What NAKO Gesundheitsstudie does
NAKO Gesundheitsstudie (German National Cohort), legally organized as NAKO e.V., is a Heidelberg-based non-profit research association established in 2014 to operate Germany's largest population-based prospective epidemiological cohort study. The study randomly enrolled over 200,000 participants aged 20-69 across 18 study centers nationwide, conducting comprehensive medical examinations (including imaging, multi-omics sampling, accelerometry, and environmental exposure assessments) at baseline and follow-up intervals of every five years. The underlying infrastructure comprises the NAKO Biorepository at Helmholtz Munich for biological sample storage, the NAKO TransferHub for researcher data access applications, the myNAKO participant portal, and the YoungNAKO graduate training program.
NAKO e.V. does not operate a commercial business model. The organization is financed through public funds from the Federal Ministry of Research, Technology and Space (BMFTR), the Helmholtz Association, and participating federal states, with 26 institutional research partners (universities, Helmholtz-Gemeinschaft, Leibniz-Gemeinschaft) executing the work. Its primary "customer" segments are the general German population (study participants contributing data) and academic researchers who apply for access to the longitudinal dataset through formal application processes. The organization is currently conducting its third examination phase (Drittuntersuchung) and was designated a central component of the federal National Decade against Post-Infectious Diseases initiative in 2025/2026.
The board is chaired by Prof. Dr. Annette Peters (Director of the Institute of Epidemiology at Helmholtz Munich), with Prof. Dr. Wolfgang Lieb, Prof. Dr. Tobias Pischon, and Prof. Dr. Tamara Schikowski serving as scientific board members and Dr. Esther Breunig as administrative board member. The association's headcount of 30 reflects its lean central coordinating body, with the bulk of operational capacity distributed across the 18 study centers and 26 partner institutions.
NAKO Gesundheitsstudie firmographics
Firmographics- Name
- NAKO Gesundheitsstudie
- Legal name
- NAKO e.V.
- Website
- https://nako.de
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NAKO Gesundheitsstudie is a German non-profit research association operating the country's largest population-based longitudinal health cohort study, following 200,000+ participants across 18 study centers and serving academic researchers with access to multi-omics, imaging, and survey data.
- Ownership category
- akta.pro rank
NAKO Gesundheitsstudie industry classification
Industry- Product category
- Population Health Research
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Web Search Portals, Libraries, Archives, and Other Information Services (519), Newspaper, Periodical, Book, and Directory Publishers (5131)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Population Health Surveillance & Epidemiologic Analytics (HLAJAJAB)
- akta.pro secondary industries
- Data Linkage, Registries & Longitudinal Cohort Surveillance (HLAJANAM), Health Statistics & Reporting (National/State/Local Indicators) (HLAJAJAC), Behavioral Risk & Health Survey Surveillance (HLAJANAD), Census, Demographic & Community Health Needs Assessment (CHNA) (HLAJAJAH), Health Data, Vital Statistics & Population Health Informatics (BPAIAJAM)
Keywords
NAKO Gesundheitsstudie business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Distribution channels1 record
Marketing channels10 records
NAKO Gesundheitsstudie product offering
Product offeringCore offering
NAKO Gesundheitsstudie is Germany's largest population-based prospective epidemiological cohort study, medically examining and surveying over 200,000 randomly selected participants aged 20-69 across 18 study centers since 2014 with follow-up examinations every five years. The study collects comprehensive medical examination data, lifestyle questionnaires, biosamples stored in a centralized biorepository, and multi-omics and imaging data to investigate risk factors and causes of common diseases such as cancer, diabetes, and cardiovascular conditions. Researchers access NAKO data through the NAKO TransferHub, while participants engage via the myNAKO portal.
Product overview
NAKO Gesundheitsstudie operates as a unified research infrastructure combining population-based longitudinal cohort research with supporting services and platforms. The core offering is the German National Cohort study, which follows over 200,000 participants through comprehensive medical examinations and surveys. This core is supported by the myNAKO participant portal for participant management, the NAKO TransferHub for researcher data access, and consultation services for research support. Additional offerings include the YoungNAKO graduate programme for researcher training, the NAKO Biorepository for biological sample storage, research newsletters, and annual international conferences. The study provides researchers with access to diverse data types including accelerometry, genomics, environmental data, and imaging data.
Differentiator
Problem solved
Functional benefit
Brands
- myNAKO: Participants portal for NAKO study participants to access their data and information
- YoungNAKO
- NAKO TransferHub
- International NAKO Conference
Products and services
- NAKO Gesundheitsstudie (German National Cohort) Population-based prospective epidemiological cohort study medically examining and surveying over 200,000 randomly selected participants aged 20-69 across 18 study centers, with follow-up examinations every five years to investigate risk factors and causes of common diseases.
- NAKO TransferHub Online platform providing researchers with access to NAKO data, documentation, application processes, and consultation services for data use requests.
- NAKO Consultation Service Remote consultation appointments via Microsoft Teams for researchers seeking guidance on NAKO services, data applications, and research support, available Wednesdays and Fridays from 9am-2pm CET.
- myNAKO Participant Portal Online portal for study participants to access their information, manage participation details, and communicate with study centers.
- YoungNAKO Graduate Programme Graduate program for early-career researchers focusing on population-based cohort studies, including training modules on biosample collection, analysis pipelines, and cohort research methodologies.
- NAKO Research Newsletter English-language newsletter providing researchers with updates on NAKO studies, new data releases, research findings, and conference information.
- NAKO Biorepository Centralized storage facility for biological samples collected during participant examinations, located at Helmholtz Munich, providing sample processing and storage for research analysis.
- International NAKO Conference Annual international scientific conference organized by NAKO e.V., bringing together researchers to share findings, build collaborations, and discuss the future of population health research using NAKO data.
Companies that use NAKO Gesundheitsstudie
Customer profileSegments1 record
Ideal customer profiles1 record
NAKO Gesundheitsstudie technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration10 records
Feature4 records
NAKO Gesundheitsstudie partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights4 records
NAKO Gesundheitsstudie competitors and assessment
Company assessmentEmerging players
- FinnGen: Public-private Finnish genomics project combining biobank samples with national health registry data at population scale. Comparable population-genomics orientation with strong biobank and registry linkage, though with a genomics-first rather than multi-omics design.
Direct peers
- China Kadoorie Biobank: Prospective cohort of ~512,000 Chinese adults with baseline measures, biosamples, and long-term follow-up via linkage to mortality and morbidity registries. Comparable in scale, structure, and chronic-disease research focus to NAKO.
- Lifelines: Netherlands population-based three-generation cohort of ~167,000 participants with biosamples, genetics, and follow-up. Comparable European regional cohort with similar multi-modal data collection and population-based recruitment model.
- EPIC (European Prospective Investigation into Cancer and Nutrition): Multi-country European prospective cohort investigating diet, lifestyle, and cancer with ~500,000 participants across 10 countries. Comparable European longitudinal cohort design with biosamples and disease-specific focus.
- UK Biobank: UK population-based prospective cohort of ~500,000 participants with deep phenotyping, biosamples, and linked health records. The most directly comparable large-scale national cohort infrastructure and the benchmark NAKO is positioned alongside in the international cohort ecosystem.
- Canadian Partnership for Tomorrow Project: Canada's largest population-based cohort harmonizing regional cohorts with ~300,000 participants and biosamples. National-scale publicly funded cohort with similar data-access mechanisms and longitudinal follow-up.
- All of Us Research Program (NIH): US federally funded longitudinal program aiming to enroll 1 million+ diverse participants with genomic, EHR, and survey data. Directly comparable mission and structure to NAKO, with similar longitudinal cohort design and public funding model.
Regional players
- Estonian Biobank (EstBB): Population-based biobank of ~200,000 Estonian participants linked to national EHR and genomic data. Comparable in scale and biobank-centric design; smaller national population, similar pan-European research positioning.
Others
- Helmholtz Munich: NAKO e.V. operates within the broader Helmholtz Association ecosystem and hosts the NAKO Biorepository at Helmholtz Munich. Helmholtz Munich provides scientific governance infrastructure and is comparable as the parent research environment that anchors NAKO operations.
Broad incumbents
- The Rotterdam Study: Long-running prospective population-based cohort in the Netherlands focusing on chronic diseases in the elderly. Comparable population-cohort methodology and chronic-disease research orientation, though smaller and more focused than NAKO.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
NAKO Gesundheitsstudie social profiles
Digital presenceNAKO Gesundheitsstudie compliance and trust
Trust signalCompliance1 record
NAKO Gesundheitsstudie financial estimates
Financial estimateRevenue estimate
Valuation estimate
NAKO Gesundheitsstudie leadership team
Management profileNumber of profiles
Profiles6 records
NAKO Gesundheitsstudie funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NAKO Gesundheitsstudie M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NAKO Gesundheitsstudie
What does NAKO Gesundheitsstudie do?
NAKO Gesundheitsstudie is Germany's largest population-based prospective epidemiological cohort study, medically examining and surveying over 200,000 randomly selected participants aged 20-69 across 18 study centers since 2014 with follow-up examinations every five years. The study collects comprehensive medical examination data, lifestyle questionnaires, biosamples stored in a centralized biorepository, and multi-omics and imaging data to investigate risk factors and causes of common diseases such as cancer, diabetes, and cardiovascular conditions. Researchers access NAKO data through the NAKO TransferHub, while participants engage via the myNAKO portal.
Is NAKO Gesundheitsstudie a public or private company?
NAKO Gesundheitsstudie is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was NAKO Gesundheitsstudie founded?
NAKO Gesundheitsstudie was founded in 2014. It employs 11 to 50 people.
Who are NAKO Gesundheitsstudie's main competitors?
FinnGen is listed as an emerging player. Direct peers are China Kadoorie Biobank, Lifelines, EPIC (European Prospective Investigation into Cancer and Nutrition), UK Biobank, Canadian Partnership for Tomorrow Project and All of Us Research Program (NIH). Estonian Biobank (EstBB) is listed as a regional player. Helmholtz Munich is listed as an others. The Rotterdam Study is listed as a broad incumbent.
Does NAKO Gesundheitsstudie have an API?
No public API is recorded for NAKO Gesundheitsstudie.
What industry is NAKO Gesundheitsstudie in?
NAKO Gesundheitsstudie's product category is Population Health Research. Its primary akta.pro industry code is HLAJAJAB, Population Health Surveillance & Epidemiologic Analytics, with a secondary code of HLAJANAM, Data Linkage, Registries & Longitudinal Cohort Surveillance. Its NAICS code is 541714 and its SIC code is 8731.